Invesco Exchange-traded Fund Trust Ii · net assets $67.4M · 261 holdings as of May 31, 2026. Monthly N-PORT disclosure: the full book, not just equities.
EC: 83.5% · STIV: 16.5%
| Month 1 | Month 2 | Month 3 | |
|---|---|---|---|
| Sales | $0 | $0 | $0 |
| Reinvestment | $0 | $0 | $0 |
| Redemptions | $0 | $7.6M | $0 |
| Net realized gain (non-derivative) | $37.5K | $3.03M | $155K |
| Net unrealized appreciation (non-derivative) | $-2.56M | $-2.74M | $1.27M |
The three months of the reporting period, as filed; month 3 ends May 31, 2026.
| Holding | Value | % of net assets |
|---|---|---|
| Invesco Private Prime Fund STIV | $9.57M | 14.20% |
| Gilead Sciences, Inc. EC | $4.98M | 7.39% |
| Vertex Pharmaceuticals Inc. EC | $4.97M | 7.38% |
| Amgen Inc. EC | $4.79M | 7.10% |
| Invesco Private Government Fund STIV | $3.69M | 5.48% |
| Regeneron Pharmaceuticals, Inc. EC | $3.42M | 5.08% |
| Alnylam Pharmaceuticals, Inc. EC | $2.15M | 3.19% |
| Revolution Medicines, Inc. EC | $1.67M | 2.48% |
| Biogen Inc. EC | $1.54M | 2.29% |
| Illumina, Inc. EC | $1.34M | 1.98% |
| United Therapeutics Corp. EC | $1.31M | 1.94% |
| Royalty Pharma PLC EC | $1.28M | 1.90% |
| Argenx Se EC | $1.27M | 1.89% |
| Insmed Inc. EC | $1.24M | 1.83% |
| Roivant Sciences Ltd. EC | $1.15M | 1.71% |
| Incyte Corp. EC | $1.03M | 1.53% |
| Viatris Inc. EC | $1M | 1.49% |
| Moderna, Inc. EC | $999K | 1.48% |
| Guardant Health, Inc. EC | $912K | 1.35% |
| Neurocrine Biosciences, Inc. EC | $852K | 1.26% |
| Jazz Pharmaceuticals PLC EC | $780K | 1.16% |
| Ascendis Pharma A/s EC | $740K | 1.10% |
| Summit Therapeutics Inc. EC | $729K | 1.08% |
| Exelixis, Inc. EC | $703K | 1.04% |
| Bridgebio Pharma, Inc. EC | $689K | 1.02% |
| Medpace Holdings, Inc. EC | $681K | 1.01% |
| Ionis Pharmaceuticals, Inc. EC | $677K | 1.01% |
| Axsome Therapeutics, Inc. EC | $643K | 0.95% |
| Madrigal Pharmaceuticals, Inc. EC | $612K | 0.91% |
| Biomarin Pharmaceutical Inc. EC | $591K | 0.88% |
| Biontech Se EC | $586K | 0.87% |
| Arrowhead Pharmaceuticals, Inc. EC | $585K | 0.87% |
| Sanofi EC | $573K | 0.85% |
| Praxis Precision Medicines, Inc. EC | $523K | 0.78% |
| Cytokinetics, Inc. EC | $506K | 0.75% |
| Beone Medicines Ltd. EC | $493K | 0.73% |
| Krystal Biotech, Inc. EC | $484K | 0.72% |
| Tempus Ai, Inc. EC | $470K | 0.70% |
| Abivax S.a. EC | $437K | 0.65% |
| Nuvalent, Inc. EC | $433K | 0.64% |
| Halozyme Therapeutics, Inc. EC | $421K | 0.62% |
| Immunitybio, Inc. EC | $414K | 0.62% |
| Vaxcyte, Inc. EC | $397K | 0.59% |
| Alkermes PLC EC | $377K | 0.56% |
| Immunovant, Inc. EC | $363K | 0.54% |
| Kymera Therapeutics, Inc. EC | $356K | 0.53% |
| Protagonist Therapeutics, Inc. EC | $341K | 0.51% |
| Mirum Pharmaceuticals, Inc. EC | $328K | 0.49% |
| Ptc Therapeutics, Inc. EC | $327K | 0.49% |
| Rhythm Pharmaceuticals, Inc. EC | $323K | 0.48% |
| Spyre Therapeutics, Inc. EC | $309K | 0.46% |
| Cogent Biosciences, Inc. EC | $304K | 0.45% |
| Crispr Therapeutics Ag EC | $289K | 0.43% |
| Cg Oncology, Inc. EC | $282K | 0.42% |
| Scholar Rock Holding Corp. EC | $269K | 0.40% |
| Centessa Pharmaceuticals PLC EC | $255K | 0.38% |
| Caris Life Sciences, Inc. EC | $252K | 0.37% |
| Ligand Pharmaceuticals Inc. EC | $248K | 0.37% |
| Xenon Pharmaceuticals Inc. EC | $244K | 0.36% |
| Indivior Pharmaceuticals, Inc. EC | $241K | 0.36% |
Showing top 60 of 261 holdings.
Loading...
